🇺🇸 FDA
Pipeline program

Dexmedetomidine

201707158

Approved small_molecule terminated

Quick answer

Dexmedetomidine for Thoracic Paravertebral Blocks is a Approved program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Thoracic Paravertebral Blocks
Phase
Approved
Modality
small_molecule
Status
terminated

Clinical trials